[Randomized Clinical Trial for Treatment of Patients with Acute Ischemic Cerebral Stroke by Acupoint Injection of Cobalamin or Gangliosides].
To observe the clinical therapeutic effect of acupoint injection of medicine in the treatment of patients with acute cerebral ischemia stroke (ACIS). Ninety ACIS patients were randomized into control, Cobalamin and Gangliosides groups (n=30 in each group). Patients of the control group were treated by routine medication (i.e., drugs for improving microcirculation, anti-platelet aggregation, cerebral dehydration, neuronutrition, intracranial pressure reduction and blood lipid-lowering, etc.) and motor function rehabilitation training, once daily, six times a week for two weeks; and those of the Cobalamin and Gangliosides groups were treated by injection of Cobalamin (1 mL) or Gangliosides (1 mL) into Baihui (GV 20) and Zusanli (ST 36), respectively and rehabilitation training (being the same to the control group). The patients' motor ability and physical status were assessed according to clinical neurologic deficit score (CNDS) and activity of daily living scale (ADLS). After the treatment, of the three 30 cases in the control, Cobalamin and Gangliosides groups, 0, 4 and 2 were cured, 9, 15 and 14 experienced marked improvement in their symptoms, 12, 8 and 10 were improved, 9, 3 and 4 invalid, with the effective rates being 70.0%(21/30), 90.0%(27/30) and 86.7%(26/30), respectively. In comparison with pre-treatment, the CNDS of the three groups were all significantly decreased and the ADLS notably increased (P<0.05). The effects of both Cobalamin and Gangliosides were remarkably better than those of the control in lowering CNDS and raising ADLS (P<0.05), and the score of ADLS in the Cobalamin group was markedly higher than that in the Gangliosides group (P<0.05). Acupoint injection of both Cobalamin and Gangliosides can effectively improve acute ischemic stroke patients' neurological function and daily life living ability.